irinotecan has been researched along with alvocidib in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Gonen, M; Jung, C; Motwani, M; Schwartz, GK; Shah, MA; She, Y; Sirotnak, FM | 1 |
| Commes, T; Motwani, M; Schwartz, GK; She, Y; Sirotnak, FM | 1 |
| Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U | 1 |
| Fortier, LC; Gagné, JF; Girard, H; Guillemette, C; Villeneuve, L | 1 |
| Brenner, B; Cordon-Cardo, C; Drobnjak, M; Gonen, M; Kelsen, DP; Kortmansky, J; Lefkowitz, R; Motwani, M; O'Reilly, E; Saltz, L; Schwartz, GK; Shah, MA; Tong, W; Weyerbacher, A; Yi, S | 1 |
| Ambrosini, G; Qin, LX; Schwartz, GK; Seelman, SL | 1 |
| Ashwell, S; Brassil, PJ; Dai, J; Garner, CE; Gönen, M; Goteti, K; Kern, SE; Moustakas, DT; Schwartz, GK; Utley, L; Zabludoff, S | 1 |
| Chyi Lee, F; Fekrazad, HM; Rabinowitz, I; Royce, M; Smith, HO; Verschraegen, CF | 1 |
| Belcastro, V; Bosotti, R; Brunetti-Pierri, N; di Bernardo, D; Ferriero, R; Iorio, F; Isacchi, A; Mithbaokar, P; Murino, L; Scacheri, E; Tagliaferri, R | 1 |
| Cane, LM; Carvajal, RD; Dials, HJ; Dickson, MA; Gonen, M; Lefkowitz, RA; Rathkopf, D; Schwartz, GK; Shah, MA; Tse, A; Wu, N | 1 |
| Ackerstaff, E; Chen, JH; Darpolor, MM; Kennealey, PT; Koutcher, JA; Le, HC; Rizwan, A; Sambol, EB; Schwartz, GK; Singer, S; Zakian, KL | 1 |
1 review(s) available for irinotecan and alvocidib
| Article | Year |
|---|---|
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 2; Deoxycytidine; Drug Administration Schedule; Enzyme Inhibitors; Flavonoids; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Isoenzymes; Leucovorin; Membrane Proteins; Organoplatinum Compounds; Oxaliplatin; Piperidines; Prostaglandin-Endoperoxide Synthases; Quinazolines; Thiophenes; Treatment Outcome | 2003 |
3 trial(s) available for irinotecan and alvocidib
| Article | Year |
|---|---|
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p21; Drug Administration Schedule; Drug Interactions; Female; Flavonoids; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Piperidines; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Gemcitabine; Humans; Irinotecan; Life Expectancy; Male; Middle Aged; Neoplasm Metastasis; Patient Selection; Piperidines | 2010 |
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Piperidines; Protein Kinase Inhibitors; Treatment Outcome | 2010 |
9 other study(ies) available for irinotecan and alvocidib
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Flavonoids; Humans; Irinotecan; Male; Mice; Mice, Nude; Piperidines; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; DNA, Antisense; DNA, Complementary; Drug Synergism; Flavonoids; GTP-Binding Proteins; Humans; Irinotecan; Male; Mice; Mice, Nude; Piperidines; Prodrugs; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.
Topics: Alleles; Amino Acid Sequence; Antineoplastic Agents; Binding, Competitive; Black People; Blotting, Western; Camptothecin; Flavonoids; Glucuronates; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Kinetics; Molecular Sequence Data; Mutation, Missense; Piperidines; Polymorphism, Genetic; Recombinant Proteins; Sequence Homology, Amino Acid; Subcellular Fractions; UDP-Glucuronosyltransferase 1A9; White People | 2003 |
The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Cyclin-Dependent Kinase 9; Down-Regulation; Drug Synergism; Flavonoids; HCT116 Cells; Humans; Irinotecan; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Rad51 Recombinase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2008 |
Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Flavonoids; Genes, cdc; Growth Inhibitors; Humans; Irinotecan; Mice; Mice, Nude; Models, Statistical; Neoplasm Transplantation; Piperidines; Predictive Value of Tests; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2010 |
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Algorithms; Antineoplastic Agents; Autophagy; Blotting, Western; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Discovery; Drug Screening Assays, Antitumor; Flavonoids; Fuzzy Logic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Irinotecan; Neoplasms; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperidines; Pyrazoles; Pyrroles; RNA Polymerase II | 2010 |
Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Choline Kinase; Choline-Phosphate Cytidylyltransferase; Colorectal Neoplasms; Female; Flavonoids; HCT116 Cells; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Mice; Phosphorus Isotopes; Piperidines; Protons; Saccharomyces cerevisiae; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |